CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $532,138 | +157.1% | 17,893 | +38.9% | 0.12% | +7.1% |
| Q1 2023 | $206,949 | -86.1% | 12,886 | -84.2% | 0.11% | -84.8% |
| Q4 2022 | $1,490,828 | +55.1% | 81,466 | +66.5% | 0.74% | +120.4% |
| Q3 2022 | $961,000 | -12.1% | 48,925 | -16.5% | 0.34% | -29.3% |
| Q2 2022 | $1,093,000 | -3.4% | 58,601 | +13.7% | 0.48% | -9.6% |
| Q1 2022 | $1,131,000 | -0.4% | 51,536 | +28.9% | 0.53% | +178.4% |
| Q4 2021 | $1,136,000 | – | 39,989 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |